Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mariotti, C.
Right arrow Articles by Di Donato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mariotti, C.
Right arrow Articles by Di Donato, S.
Related Collections
Right arrow Tremor
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow Trinucleotide repeat diseases

Neurology 2003;60:1676-1679
© 2003 American Academy of Neurology
Brief Communications

Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial

C. Mariotti, MD, A. Solari, MD, D. Torta, MD, L. Marano, MD, C. Fiorentini, MD and S. Di Donato, MD

From the Division of Biochemistry and Genetics (Drs. Mariotti and Di Donato) and Unit of Neuro-Epidemiology (Dr. Solari), Carlo Besta National Neurological Institute–IRCCS, Milan; and Division of Cardiology (Drs. Torta, Marano, and Fiorentini), San Paolo Hospital, University of Milan, Italy.

Address correspondence and reprint requests to Dr. Stefano Di Donato, Divisione di Biochimica e Genetica, Istituto Nazionale Neurologico Carlo Besta–IRCCS, via Celoria 11, 20133 Milano, Italy; e-mail: didonato{at}istituto-besta.it

The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia. They found significant reductions of interventricular septal thickness and left ventricular mass in the idebenone group vs the placebo group, with no improvement in other heart ultrasound measures or neurologic condition. The absolute cardiac changes were modest, but the findings suggest that larger trials should assess whether idebenone reduces ventricular hypertrophy in patients with Friedreich ataxia.




This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
S. Al-Mahdawi, R. M. Pinto, O. Ismail, D. Varshney, S. Lymperi, C. Sandi, D. Trabzuni, and M. Pook
The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues
Hum. Mol. Genet., March 1, 2008; 17(5): 735 - 746.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
N. A. Di Prospero, C. J. Sumner, S. R. Penzak, B. Ravina, K. H. Fischbeck, and J. P. Taylor
Safety, Tolerability, and Pharmacokinetics of High-Dose Idebenone in Patients With Friedreich Ataxia
Arch Neurol, June 1, 2007; 64(6): 803 - 808.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
P. Ribai, F. Pousset, M.-L. Tanguy, S. Rivaud-Pechoux, I. Le Ber, F. Gasparini, P. Charles, A.-S. Beraud, M. Schmitt, M. Koenig, et al.
Neurological, Cardiological, and Oculomotor Progression in 104 Patients With Friedreich Ataxia During Long-term Follow-up
Arch Neurol, April 1, 2007; 64(4): 558 - 564.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. F. Cox, L. A. Sleeper, A. M. Lowe, J. A. Towbin, S. D. Colan, E. J. Orav, P. R. Lurie, J. E. Messere, J. D. Wilkinson, and S. E. Lipshultz
Factors Associated With Establishing a Causal Diagnosis for Children With Cardiomyopathy
Pediatrics, October 1, 2006; 118(4): 1519 - 1531.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. M. James, H. M. Cocheme, R. A. J. Smith, and M. P. Murphy
Interactions of Mitochondria-targeted and Untargeted Ubiquinones with the Mitochondrial Respiratory Chain and Reactive Oxygen Species: IMPLICATIONS FOR THE USE OF EXOGENOUS UBIQUINONES AS THERAPIES AND EXPERIMENTAL TOOLS
J. Biol. Chem., June 3, 2005; 280(22): 21295 - 21312.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
P. E. Hart, R. Lodi, B. Rajagopalan, J. L. Bradley, J. G. Crilley, C. Turner, A. M. Blamire, D. Manners, P. Styles, A. H. V. Schapira, et al.
Antioxidant Treatment of Patients With Friedreich Ataxia: Four-Year Follow-up
Arch Neurol, April 1, 2005; 62(4): 621 - 626.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
M. R. Golomb, A. Illner, C. K. Christensen, and L. E. Walsh
A Child With Friedreich's Ataxia and Epilepsy
J Child Neurol, March 1, 2005; 20(3): 248 - 250.
[Abstract] [PDF]

Home page
 Hum Mol GenetHome page
H. Seznec, D. Simon, C. Bouton, L. Reutenauer, A. Hertzog, P. Golik, V. Procaccio, M. Patel, J.-C. Drapier, M. Koenig, et al.
Friedreich ataxia: the oxidative stress paradox
Hum. Mol. Genet., February 15, 2005; 14(4): 463 - 474.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. Zeviani and S. Di Donato
Mitochondrial disorders
Brain, October 1, 2004; 127(10): 2153 - 2172.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Rustin, D. Bonnet, A. Rotig, A. Munnich, D. Sidi, C. Mariotti, F. Taroni, S. Di Donato, A. Filla, and A. J. Moss
Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial
Neurology, February 10, 2004; 62(3): 524 - 525.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. Filla and A. J. Moss
Idebenone for treatment of Friedreich's ataxia?
Neurology, May 27, 2003; 60(10): 1569 - 1570.
[Full Text] [PDF]